AKT1 and melanoma: Shi et al. in the attempt to identify early events occurring in patient’s melanomas shortly after exposure to BRAFi or BRAFi/MEKi, found that Akt activity is engaged in drug-naïve tumors shortly after the beginning of treatments [294].